Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.63 |
| ▸ | HTR1A | P08908 | 6/20 | 0.56 |
| ▸ | HTR3A | P46098 | 6/20 | 0.56 |
| ▸ | HTR7 | P34969 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6739727 | 0.98 | ADRB1 (0.61) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| Acetamide SCHEMBL3242644 | 0.88 | ADRB1 (0.51) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| SCHEMBL10836444 | 0.87 | ADRB1 (0.55) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| SCHEMBL532400 | 0.87 | ADRB1 (0.54) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| SCHEMBL8700015 | 0.84 | HTR3A (0.58) | ADRB1HTR1AHTR3AHTR7HTR3E | |
| SCHEMBL30164060 | 0.82 | ADRB1 (0.50) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| SCHEMBL28499540 | 0.82 | ADRB1 (0.50) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| SCHEMBL5745223 | 0.81 | ADRB1 (0.49) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| SCHEMBL3951662 | 0.80 | ADRB1 (0.47) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| SCHEMBL1742849 | 0.80 | ADRB1 (0.47) | ADRB1HTR1AHTR3AHTR7CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10125226-B2 | Scale-up process of bifunctionalized triblock copolymers with secondary and tertiary amines, with application in dewatering and desalting of heavy crude oils | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2018-11-13 | — | — | US | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| EP-1204677-B1 | CYCLOHEXAPEPTIDE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL | AVENTIS PHARMA GMBH (DE) | 2008-12-03 | — | — | EP | claimed |
| US-7166572-B1 | Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | claimed |
| EP-1204677-A2 | CYCLOHEXAPEPTIDE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2002-05-15 | — | — | EP | claimed |
| WO-2001007468-A2 | NOVEL CYCLOHEXAPEPTIDE COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-02-01 | — | — | WO | claimed |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | UNIV JOHNS HOPKINS (US) | 2026-04-02 | — | — | US | disclosed |
| US-12527746-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-01-20 | — | — | US | disclosed |
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4642434-A2 | LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-0244175-A2 | Furo (3,4-d) pyrimidine-2, 4-dione derivatives and intermediates thereof | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4703120-A | VASODILATORS, HYPOTENSIVE AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-10-27 | — | — | US | disclosed |
| US-4547505-A | ANTIULCER, ANTIPHLOGISTIC, AND ANTISECRETORY AGENT | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1985-10-15 | — | — | US | disclosed |
| US-4370329-A | Piperazine derivatives as circulation-enhancing substances | MERZ & COMPANY (DE) | 1983-01-25 | — | — | US | disclosed |
| US-4370330-A | Method of enhancing circulation with piperazines | MERZ & COMPANY (DE) | 1983-01-25 | — | — | US | disclosed |
| US-3948898-A | HYPOTENSIVES, SEDATIVES, ANTIARRHYTHMICS, BRADYCARDIACS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | ADRB1 79/4885HTR1A 4/4885HTR3A 12/4885 |
| US-12527746-B2 | Peptide/particle delivery systems | VEGFA, IGF2BP2, MSTN | ADRB1 1326/4885HTR1A 1346/4885HTR3A 2147/4885 |
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | SLC43A1, SLC7A5, SLC7A1 | ADRB1 961/4885HTR1A 4712/4885HTR3A 4257/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | ADRB1 1031/4885HTR1A 3639/4885HTR3A 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.